Probiotics for Corals Boost Resilience, Help Prevent Mortality
18.8.2021 10:00:00 EEST | Business Wire | Press release
A new study shows probiotics to be helpful protagonists in boosting coral health and preventing mortality in the face of environmental stressors, such as warming oceans and changing climate conditions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210818005016/en/
KAUST Marine Scientist Dr. Raquel Peixoto administers probiotics, or Beneficial Microorganisms for Corals (BMC), to Pocillopora verrucosa coral in controlled aquarium environments. (Photo: KAUST)
Published in Science Advances, the study details research conducted by the Federal University of Rio de Janeiro, Brazil, in collaboration with the Red Sea Research Center at King Abdullah University of Science and Technology (KAUST). It is the first of its kind to show that Beneficial Microorganisms for Corals (BMC) can protect bleached corals from death, by stimulating immune processes that help them rebuild their microbiome environment and offset “post-heat stress disorder” symptoms driven by thermal stress.
The scientists created a probiotic using microbes derived from the coral itself, selecting strains with traits deemed likeliest to boost resilience. They isolated, plated and studied hundreds of bacteria strains for their potential to serve as BMCs. They inoculated two groups of corals in controlled environments—those with probiotics and those with a placebo, exposing both to the same degree of thermal stress. Probiotics increased the stability and survivorship in the algae-coral host relationship by more than 40%.
Dr. Raquel Peixoto, lead author and KAUST marine scientist, said, “Whereas all corals initially bleached and showed signs of stress, those with BMCs survived and returned to their original state, with results similar to corals that had not been exposed at all. Corals without BMCs sustained damage or died. The holistic formula equipped the corals with hearty traits for buffering and surviving heat trauma.”
Contributing author Dr. Chris Voolstra, reef genomicist and big data specialist, said, “The study is remarkable for demonstrating ‘genetic reprogramming,’ meaning, microbes prompt the coral to make beneficial changes at the genetic level rather than superimpose their functions onto the host. This is a key understanding about the mechanisms underlying coral probiotics that was not known before.”
The study received funding from the Great Barrier Reef Foundation’s Out of the Blue Box Reef Innovation Challenge, for new ideas to protect coral reefs, and was supported by the Tiffany & Co Foundation.
Great Barrier Reef Foundation Managing Director Anna Marsden said, “Pioneering science such as this provides hope for the future of the Great Barrier Reef and coral reefs globally, which are coming under increasing pressure from climate change.”
Read the full article here.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210818005016/en/
Contact information
Najdat Boukarroum
Najdat.boukarroum@kaust.edu.sa
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 Data for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)6.5.2026 02:00:00 EEST | Press release
Samsung Bioepis Co., Ltd. announced today that the Phase 1 study on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), has met its primary pharmacokinetics (PK) endpoints. The randomized, double-blind, three-arm, parallel group, multicenter clinical trial demonstrated pharmacokinetic bioequivalence of SB27 (pembrolizumab) to the reference product Keytruda. Initiated in January 2024, Phase 1 study is being conducted in four countries, and is expected to be completed by November 2026.2 The study assessed pharmacokinetics, efficacy, safety, and immunogenicity of SB27, EU-sourced Keytruda, and US-sourced Keytruda in patients with stage II or IIIA non-small cell lung cancer (NSCLC) following complete resection and adjuvant platinum-based chemotherapy. 163 participants were randomized to receive SB27, EU-sourced Keytruda, or US-sourced Keytruda every 3 weeks, maximum 18 cycles over about 51 weeks, and blood samples were collected. The preliminary pharmacokinetic evaluation indicates t
Megaport Launches Built-In DDoS Protection Enabling On-Demand Network Resilience6.5.2026 01:00:00 EEST | Press release
Megaport Limited (ASX: MP1) (“Megaport”), a leading global automated infrastructure platform, today announced the launch of Megaport DDoS Protection. This new, built-in security capability for Megaport Internet allows customers to filter malicious traffic directly within the Megaport network rather than routing it through a separate or external service, for mission-critical uptime without introducing additional latency or routing complexity. As enterprises increasingly migrate to distributed cloud environments, traditional DDoS mitigation has struggled to keep pace with cloud and distributed infrastructure adoption. Standard ISP solutions often resort to dropping all traffic and taking the service offline to protect the network, while external third-party providers force a "security detour" that reroutes traffic through public infrastructure, introducing significant latency and complexity. Megaport DDoS Protection removes these challenges by integrating fabric-native protection directl
IFF Reports First Quarter 2026 Results5.5.2026 23:23:00 EEST | Press release
IFF (NYSE: IFF) reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Consolidated Summary: Management Commentary “IFF is off to a solid start in 2026, with first quarter results that reflect the customer focus and operational execution we’ve been building across the company,” said Erik Fyrwald, CEO of IFF. “We delivered volume growth in all four segments, improved profitability, and generated strong cash flow in the first quarter. As we look ahead, we are maintaining a disciplined approach to how we are planning the balance of the year as the current operating environment remains unsettled. We remained focused on advancing our commercial and innovation pipelines, driving productivity, and working with customers to offset inflation. This – when combined with our solid start to the year – derisks the balance of the year and gives us the confidence to reaffirm our full-year 2026 financial guidance ranges in an uncertain environment. At the same time, w
Logitech Announces Q4 and Full Fiscal Year 2026 Results5.5.2026 23:06:00 EEST | Press release
SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the fourth quarter and full Fiscal Year 2026. For Fiscal Year 2026: Sales were $4.84 billion, up 6 percent in US dollars and 4 percent in constant currency compared to the prior year. GAAP operating income was $775 million, up 18 percent compared to the prior year. Non-GAAP operating income was $911 million, up 18 percent compared to the prior year. GAAP earnings per share was $4.80, up 16 percent compared to the prior year. Non-GAAP EPS was $5.78, up 19 percent compared to the prior year. Cash flow from operations was $1.04 billion. The year-ending cash balance was $1.7 billion. The Company returned $768 million of cash to shareholders through its annual dividend payment and share repurchases. For Q4 Fiscal Year 2026: Sales were $1.09 billion, up 7 percent in US dollars and 3 percent in constant currency compared to Q4 of the prior yea
Sentinel Midstream Advances Texas GulfLink Deepwater Port5.5.2026 23:00:00 EEST | Press release
Sentinel Midstream LLC (Sentinel) today announced the commencement of its Texas GulfLink deepwater port (Texas GulfLink or the Project), marking a significant milestone enabled by funding received pursuant to the U.S.—Japan Trade Agreement. The project advances in coordination with the U.S. Department of Commerce and the Government of Japan and reflects the shared commitment to strengthening global energy security and expanding U.S. export infrastructure. Sentinel will lead the development of Texas GulfLink, overseeing construction, commercial operations, and long-term management of the terminal. Funding provided under the U.S.—Japan Trade Agreement, pursuant to Executive Order 14345 signed on September 4, 2025, underscores continued international confidence in U.S. energy infrastructure and supports the expansion of American crude oil exports to global markets. Upon this commencement, Texas GulfLink will immediately begin construction of its deepwater crude oil export terminal, unlock
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
